Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support

Pharmacotherapy

Volumn 34, Issue 10, 2014, Pages e175-e179

  Cies, Jeffrey J ^a,b,c   Moore, Wayne S ^c   Dickerman, Mindy J ^a,b   Small, Christine ^a,b   Carella, Dominick ^a,b   Chopra, Arun ^d,e   Parker, Jason ^a,b  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carbapenem; ECMO; Meropenem; pediatric; pharmacodynamics; pharmacokinetic

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTERY RECONSTRUCTION; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; CARDIAC PATIENT; CASE REPORT; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TISSUE LEVEL; EXTRACORPOREAL OXYGENATION; GLENN SHUNT; HUMAN; HYPOXEMIA; INFANT; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDIATRICS; POSTOPERATIVE PERIOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PULMONARY ARTERY RECONSTRUCTION; PULMONARY HYPERTENSION; SYMPTOMATOLOGY; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRAL BRONCHIOLITIS; BLOOD; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROCLIMATE; PROCEDURES; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LIFE SUPPORT SYSTEMS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 84908200686     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1476     Document Type: Article

References (24)

1. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
2. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D,. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115: 529-35.
3. MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38: 284-8.
4. Udy AA, Roberts JA, Dewaele J, Paterson DL, Lipman J,. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
5. Goncalves-Pereira J, Povoa P,. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011; 15: R206.
6. Surviving Sepsis Campaign. International guidelines for management of severe sepsis and septic shock. Crit Care Med 2013; 41: 580-637.
7. Muszynski JA, Knatz NL, Sargel CL, Fernandez SA, Marquardt DJ, Hall MW,. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J 2011; 30: 295-301.
8. Cies JJ, Shankar V, Schlichting C, Kuti JL,. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Pediatr Infect Dis J 2014; 33: 168-73.
9. Cies JJ, Moore WS, Chopra A,. Meropenem Pharmacokinetics in Critically Ill Children [abstract 938]. Paper presented at: Society of Critical Care Medicine 43rd Annual Congress; January 2014; San Francisco, CA, USA.
10. Lipman J, Udy AA, Roberts JA,. Do we understand the impact of altered physiology, consequent interventions, and resultant clinical scenarios in ICU? The antibiotic story. Anaesth Intensive Care 2011; 39: 999-1000.
11. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
12. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
13. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
14. Amaker RD, DiPiro JT, Bhatia J,. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996; 40: 1139-42.
15. Mulla H, Pooboni S,. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005; 60: 265-75.
16. Courter JD, Kuti JL, Girotto JE, Nicolau DP,. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009; 53: 379-85.
17. Drusano GL,. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat Rev Microbiol 2004; 2: 289-300.
18. Drusano GL,. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36: 42-50.
19. Shekar K, Roberts JA, Ghassabian S, et al. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? J Antimicrob Chemother 2013; 68: 726-7.
20. Astra Zeneca Pharmaceuticals. Meropenem (Merrem) [package insert]. Wilmington, DE; 2007.
21. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL,. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011; 55: 1606-10.
22. Shekar K, Fraser JF, Smith MT, Roberts JA,. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012; 27(6): 741.e9-18. doi: 10.1016/j.jcrc.2012.02.013.
23. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
24. Shekar K, Fung YL, Diab S, et al. Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Crit Care Resusc 2012; 14: 105-11.